---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-000240"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:05:27.017337+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alaunos appoints new director, cash runway into Q3 2024, plans reverse stock split

## Summary
- Dale Curtis Hogue, Jr. appointed independent director effective Dec 29, 2023; receives initial 150k option grant vesting over 36 months.
- Cash resources expected to fund operations into Q3 2024 due to cost-saving measures.
- Company taking steps to implement reverse stock split approved by stockholders in June 2023.
- No assurance reverse split will increase stock price or cure Nasdaq listing deficiencies.

## SEC filing metadata
- accession: 0001193125-24-000240
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312524000240/0001193125-24-000240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312524000240/d682377d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-000240
- JSON: https://secwatch.observer/filing/0001193125-24-000240.json
- Plain text: https://secwatch.observer/filing/0001193125-24-000240.txt

## Key facts
- Executive change
  Dale Curtis Hogue, Jr. was appointed as director at Alaunos Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312524000240/0001193125-24-000240-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.